Publications by authors named "Kento Inada"

Claim this Profile
C
Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids.
Tomohiro Mochida, Masato Miyoshi, Sei Kakinuma, Taro Shimizu, Jun Tsuchiya, Kento Inada

Stem Cell Reports· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real-World Clinical Study.
Shun Kaneko, Yasuhiro Asahina, Miyako Murakawa, Shunsuke Ueyama, Hideki Watanabe, Kento Inada

Cancer Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic alterations in hepatocellular carcinoma after sustained virological response in relation to the molecular characterization of metabolic diseases.
Fukiko Kawai-Kitahata, Yasuhiro Asahina, Sei Kakinuma, Kento Inada, Tomohiro Mochida

Hepatol Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bile acid-FXR signaling facilitates the long-term maintenance of hepatic characteristics in human iPSC-derived organoids.
Taro Shimizu, Masato Miyoshi, Sei Kakinuma, Jun Tsuchiya, Daisuke Yamane, Kento Inada

Cell Rep· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis B Virus-KMT2B Integration Drives Hepatic Oncogenic Processes in a Human Gene-edited Induced Pluripotent Stem Cells-derived Model.
Jun Tsuchiya, Masato Miyoshi, Sei Kakinuma, Fukiko Kawai-Kitahata, Akihide Kamiya, Kento Inada

Cell Mol Gastroenterol Hepatol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High serum gamma-glutamyltransferase level after hepatitis C virus elimination is a risk factor for the development of hepatocellular carcinoma.
Miyako Murakawa, Mina Nakagawa, Hisaaki Nishimura, Shun Kaneko, Masato Miyoshi, Kento Inada

Hepatol Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A20 in hepatic stellate cells suppresses chronic hepatitis by inhibiting DCLK1-JNK pathway-dependent chemokines.
Keiya Watakabe, Masato Miyoshi, Sei Kakinuma, Ayako Sato, Jun Tsuchiya, Kento Inada

FASEB J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of C-reactive protein in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Shun Kaneko, Yasuhiro Asahina, Miyako Murakawa, Shunsuke Ueyama, Chiaki Maeyashiki, Kento Inada

Hepatol Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of prognosis and background liver disease in non-advanced hepatocellular carcinoma in two decades.
Shun Kaneko, Yasuhiro Asahina, Miyako Murakawa, Seishin Azuma, Kento Inada

PLoS One· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population.
Sakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, Mayu Higuchi, Kento Inada

Quant Imaging Med Surg· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test.
Shun Ishido, Nobuharu Tamaki, Kento Inada, Jun Itakura, Yuka Takahashi

Clin Case Rep· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
Yuka Hayakawa, Nobuharu Tamaki, Hiroyuki Nakanishi, Masayuki Kurosaki, Yuki Tanaka, Kento Inada

Intern Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy.
Taisei Keitoku, Nobuharu Tamaki, Masayuki Kurosaki, Kento Inada, Sakura Kirino

J Viral Hepat· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B.
Sakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, Shun Kaneko, Kento Inada

Hepatol Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy.
Shuhei Sekiguchi, Kaoru Tsuchiya, Yutaka Yasui, Kento Inada, Sakura Kirino

Cancer Rep (Hoboken)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simple algorithm to narrow down the candidates to receive echocardiography in patients with chronic liver disease for suspected pulmonary hypertension.
Koji Yamashita, Masayuki Kurosaki, Hiroyuki Nakanishi, Yuki Tanaka, Shun Ishido, Kento Inada

JGH Open· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease.
Kento Inada, Nobuharu Tamaki, Masayuki Kurosaki, Sakura Kirino, Koji Yamashita

J Gastroenterol Hepatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan.
Leona Osawa, Hiroyuki Nakanishi, Masayuki Kurosaki, Sakura Kirino, Kento Inada

Dig Dis· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.
Shun Kaneko, Masayuki Kurosaki, Kaoru Tsuchiya, Yutaka Yasui, Yuka Hayakawa, Kento Inada

PLoS One· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment.
Shun Kaneko, Kaoru Tsuchiya, Yutaka Yasui, Yuki Tanaka, Kento Inada

JGH Open· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
Yuka Hayakawa, Kaoru Tsuchiya, Masayuki Kurosaki, Yutaka Yasui, Shun Kaneko, Kento Inada

Invest New Drugs· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy.
Kenta Takaura, Masayuki Kurosaki, Kento Inada, Sakura Kirino, Kouji Yamashita

PLoS One· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality.
Mayu Higuchi, Nobuharu Tamaki, Masayuki Kurosaki, Kento Inada, Sakura Kirino

Aliment Pharmacol Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease.
Nobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, Yoshie Itakura, Kento Inada

J Gastroenterol Hepatol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis.
Kento Inada, Shun Kaneko, Masayuki Kurosaki, Koji Yamashita, Sakura Kirino

JGH Open· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis